Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Chief Financial Officer | October 06, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Relay Therapeutics, Inc.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,134 |
Last balance in matching sequence
After 2026-10-06 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-10-06 · Sale · Disposed 17,511 · Balance 105,340 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2: This transaction was executed in multiple trades at prices ranging from $18.20 to $19.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 6,538 shares underlying restricted stock units. Row 2 · 2026-10-06 · Sale · Disposed 206 · Balance 105,134 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F4: This transaction was executed in multiple trades at prices ranging from $19.20 to $19.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 6,538 shares underlying restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $18.20 to $19.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 6,538 shares underlying restricted stock units.
F4: This transaction was executed in multiple trades at prices ranging from $19.20 to $19.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2021 Filed Jun 10, 2021 00:33 UTC Amendment | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 22,500 | $4.12 | $92,700.00 |
DisclosureSEC source: 0001209191-21-039322 · doc4a.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2020. Read SEC document |
| March 26, 2021 Filed Mar 27, 2021 00:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 31,740 | $0.00 Strike: $34.25 | $0.00 |
DisclosureSEC source: 0001209191-21-023332 · doc4.xml · derivative · entry 2 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,740 Underlying: Common Stock · 31,740 shares Expires 2031-03-25 F2 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after March 26, 2021, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| March 26, 2021 Filed Mar 27, 2021 00:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 15,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023332 · doc4.xml · nonDerivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,870 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. The RSUs shall vest in sixteen (16) equal quarterly installments after March 26, 2021, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:30 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 63,363 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001209191-20-063482 · doc4.xml · derivative · entry 1 Catinazzo Thomas · CIK 0001818261 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,363 Underlying: Common Stock · 63,363 shares Expires 2030-03-01 F1 · shares: On March 2, 2020, the reporting person was granted an option to purchase 63,363 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 15,841 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 47,522 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date. F1 · derivative.exercise_date: On March 2, 2020, the reporting person was granted an option to purchase 63,363 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 15,841 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 47,522 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date. F1 · derivative.underlying_shares: On March 2, 2020, the reporting person was granted an option to purchase 63,363 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 15,841 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 47,522 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date. F1 · balance_after: On March 2, 2020, the reporting person was granted an option to purchase 63,363 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 15,841 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 47,522 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.